RT Journal Article
SR Electronic
T1 Rare Genomic Copy Number Variants Implicate New Candidate Genes for Bicuspid Aortic Valve
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.23.23297397
DO 10.1101/2023.10.23.23297397
A1 Carlisle, Steven G.
A1 Albasha, Hasan
A1 Michelena, Hector
A1 Sabate-Rotes, Anna
A1 Bianco, Lisa
A1 De Backer, Julie
A1 Mosquera, Laura Muiño
A1 Yetman, Anji T.
A1 Bissell, Malenka M
A1 Andreassi, Maria Grazia
A1 Foffa, Ilenia
A1 Hui, Dawn S.
A1 Caffarelli, Anthony
A1 Kim, Yuli Y.
A1 Guo, Dong-Chuan
A1 Citro, Rodolfo
A1 De Marco, Margot
A1 Tretter, Justin T.
A1 McBride, Kim L.
A1 EBAV Investigators
A1 BAVCon Investigators
A1 Milewicz, Dianna M.
A1 Body, Simon C.
A1 Prakash, Siddharth K.
YR 2023
UL http://medrxiv.org/content/early/2023/10/24/2023.10.23.23297397.abstract
AB Bicuspid aortic valve (BAV), the most common congenital heart defect, is a major cause of aortic valve disease requiring valve interventions and thoracic aortic aneurysms predisposing to acute aortic dissections. The spectrum of BAV ranges from early onset valve and aortic complications (EBAV) to sporadic late onset disease. Rare genomic copy number variants (CNVs) have previously been implicated in the development of BAV and thoracic aortic aneurysms. We determined the frequency and gene content of rare CNVs in EBAV probands (n = 272) using genome-wide SNP microarray analysis and three complementary CNV detection algorithms (cnvPartition, PennCNV, and QuantiSNP). Unselected control genotypes from the Database of Genotypes and Phenotypes were analyzed using identical methods. We filtered the data to select large genic CNVs that were detected by multiple algorithms. Findings were replicated in cohorts with late onset sporadic disease (n = 5040). We identified 34 large and rare (< 1:1000 in controls) CNVs in EBAV probands. The burden of CNVs intersecting with genes known to cause BAV when mutated was increased in case-control analysis. CNVs intersecting with GATA4 and DSCAM were enriched in cases, recurrent in other datasets, and segregated with disease in families. In total, we identified potentially pathogenic CNVs in 8% of EBAV cases, implicating alterations of candidate genes at these loci in the pathogenesis of BAV.Author Summary Bicuspid aortic valve (BAV) is the most common form of congenital heart disease and can lead to long-term complications such as aortic stenosis, aortic regurgitation, or thoracic aortic aneurysms. Most BAV-related complications arise in late adulthood, but 10-15% of individuals with BAV develop early onset complications before age 30. Copy number variants (CNVs) are genomic structural variations that have been previously implicated in some types of congenital heart disease, including BAV. Here we demonstrate that individuals with early onset complications of BAV are enriched for specific rare CNVs compared to individuals with late-onset BAV disease. We also describe novel CNVs involving DSCAM, a gene on chromosome 21 that has not previously been associated with the development of BAV. These results may lead to improved risk stratification and targeted therapies for BAV patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston reviewed and approved the study protocol.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.